Servier 1

Drug Profile

Servier 1

Alternative Names: BCL-201; S 055746; S-55746; Servier-1

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Servier; Vernalis
  • Developer Novartis Pharmaceuticals Corporation; Servier; Vernalis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Bcl-X protein inhibitors; MCL1 protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma

Most Recent Events

  • 22 Jun 2017 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Acute myeloid leukaemia and Myelodysplastic syndrome presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 22 Jun 2017 Preliminary adverse events data from a phase I trial in Chronic Lymphocytic Leukaemia presented at the 22nd Congress of the European Haematology Association (EHA - 2017)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top